NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

Stock Information for NeuroSense Therapeutics Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroSense Therapeutics Ltd.

/C O R R E C T I O N -- NeuroSense/
PrimeC New Data to Be Presented at AD/PD(TM) 2026 Conference
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.